Lomitapide

Introduction Overview

Generic Name

lomitapide

Brand Name

Juxtapid

Dosage Form

Oral capsule

Drug Class

Miscellaneous antihyperlipidemic agents

Pharmacokinetics

Absorption:
Lomitapide, administered orally as Juxtapid, exhibits rapid absorption in the gastrointestinal tract but with variable bioavailability influenced by food intake and gastrointestinal motility. It is specifically recommended to be taken on an empty stomach, at least two hours after the evening meal, to optimize absorption and reduce gastrointestinal side effects. The capsule is swallowed whole, and absorption is optimized with water intake. The presence of high-fat meals can significantly increase plasma concentrations, thereby increasing the risk of adverse reactions.

Distribution:
Following absorption, lomitapide is extensively distributed throughout body tissues, with a particular affinity for hepatic tissue due to its site of action in inhibiting microsomal triglyceride transfer protein (MTP) in the liver. Lomitapide is highly protein-bound (>99%), primarily to albumin, which affects its pharmacokinetic profile. Volume of distribution and tissue penetration beyond the liver have not been fully characterized but the hepatic distribution is clinically significant given the drug's mechanism reducing very low-density lipoprotein (VLDL) assembly.

Metabolism:
Lomitapide undergoes extensive metabolism primarily via cytochrome P450 3A4 (CYP3A4) isoenzyme in the liver. This metabolism is significant as many concomitant medications that inhibit or induce CYP3A4 can markedly alter plasma levels of lomitapide. The drug's metabolites are less pharmacologically active, and the metabolic pathway is critical to its elimination and safety profile, particularly due to potential for hepatotoxicity if levels accumulate. Interactions with strong CYP3A4 inhibitors require dose adjustment or avoidance of co-administration.

Elimination:
The drug and its metabolites are eliminated predominantly via feces, with minimal renal excretion. Lomitapide has a relatively long half-life, facilitating once-daily dosing. Liver function is essential for elimination; therefore, hepatic impairment can lead to accumulation and increased toxicity risk. Patients with abnormal liver function tests or active liver disease are contraindicated from therapy. Monitoring liver enzymes is critical throughout treatment, and dose is adjusted accordingly to maintain safety. The enterohepatic cycling may also contribute to elimination characteristics.

Dosage Forms

Available Dosage Forms:
Juxtapid is available as oral capsules in multiple strengths designed for flexible dosing and titration. The formulations include 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg capsules. Capsule shells contain gelatin and titanium dioxide, with distinct iron oxides for color differentiation depending on dose strength. Capsules are designed for oral administration and must be swallowed whole without crushing, chewing, or dissolving.

Dosages for Adults and Adolescents:
The initial adult dose of lomitapide is 5 mg taken orally once daily on an empty stomach, at least 2 hours after the evening meal, with a full glass of water. Dose titration should be individualized based on therapeutic response, tolerability, and safety monitoring, increasing gradually every 4 weeks (2 weeks after the initial dose increase) through increments of 5 mg, 10 mg, 20 mg, 40 mg, up to a maximum of 60 mg once daily. The dosing regimen must be carefully adhered to, and no pediatric dosing has been established.

Specific Patient Populations:
In patients with homozygous familial hypercholesterolemia (HoFH), Juxtapid is used in conjunction with diet and other lipid-lowering therapies. Special dosing considerations include avoiding use in patients with moderate to severe hepatic impairment or active liver disease due to increased risk of hepatotoxicity. Pregnant women are contraindicated from use, and effective contraception is mandatory for women of reproductive potential. Elderly patients require careful monitoring though no specific dosing adjustment is mandated solely on age. Renal impairment does not significantly affect lomitapide elimination, but caution is advised due to possible co-morbidities.

Mechanism Of Action

Lomitapide, the active ingredient in Juxtapid, is a selective microsomal triglyceride transfer protein (MTP) inhibitor, a unique mechanism among lipid-lowering agents. MTP is essential for the assembly and secretion of apoB-containing lipoproteins, including very low-density lipoproteins (VLDL) in the liver and chylomicrons in the intestine. By inhibiting MTP, lomitapide impairs the lipidation of apoB, preventing the formation and release of VLDL particles necessary for circulating low-density lipoprotein cholesterol (LDL-C).

At the cellular level, lomitapide blocks the transfer of triglycerides onto apoB within the endoplasmic reticulum of hepatocytes and enterocytes. This inhibition halts the secretion of VLDL from the liver and chylomicrons from the intestine into the bloodstream, thereby reducing plasma LDL-C and total cholesterol levels. This action leads to a decrease in the deposition of cholesterol on arterial walls, mitigating the progression of atherosclerosis.

Biochemically, the inhibition impacts the intracellular lipid transport pathway but does not directly alter cholesterol synthesis pathways like statins. The selective inhibition of MTP results in decreased production of apolipoprotein B-containing lipoproteins without modifying enzymes such as HMG-CoA reductase. This distinct target action allows lomitapide to act synergistically with other lipid-lowering therapies.

Clinically, lomitapide's mechanism is especially beneficial for patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition characterized by defective LDL receptor activity and impaired clearance of LDL particles. By decreasing VLDL secretion and LDL production, lomitapide reduces circulating LDL-C levels despite receptor dysfunction. Research and clinical trials have demonstrated significant LDL-C reductions in HoFH patients, making lomitapide a valuable adjunctive therapy. Comparative to other agents like statins or PCSK9 inhibitors, lomitapide offers a complementary mechanism targeting lipoprotein assembly instead of clearance or synthesis.

Pharmacological Actions

Inhibits microsomal triglyceride transfer protein (MTP) in hepatocytes and enterocytes.
Decreases assembly and secretion of apolipoprotein B-containing lipoproteins (VLDL and chylomicrons).
Lowers plasma levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol.
Reduces the intestinal absorption of dietary lipids by impairing chylomicron formation.
Acts as an adjunct therapy in homozygous familial hypercholesterolemia to reduce atherogenic lipoproteins.
Minimizes lipid accumulation on arterial walls, potentially slowing atherosclerosis progression.
Does not affect cholesterol biosynthesis pathways directly, allowing for combination with statins.
Demonstrates a novel mechanism distinct from other antihyperlipidemic agents like statins and PCSK9 inhibitors.
Provides dose-dependent lipid-lowering effects with gradual titration for safety and efficacy.
Modulates plasma lipid profile by reducing harmful apolipoprotein B lipoproteins.
May influence triglyceride levels indirectly by reducing VLDL secretion.
Has a significant hepatic distribution consistent with its site of action in lipid metabolism.
Exhibits potential hepatotoxicity linked to interference with lipid handling in liver cells.
May affect lipid-soluble vitamin levels due to altered lipoprotein metabolism.
Requires hepatic monitoring due to pharmacological influence on liver lipid processing.

Therapeutic Or Clinical Uses

Treatment of homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder with extremely high LDL cholesterol levels.
Adjunct to diet and other lipid-lowering therapies in patients with HoFH unable to achieve adequate LDL-C control.
Reduction of low-density lipoprotein cholesterol (LDL-C) and total cholesterol in patients with genetic hypercholesterolemia.
Management of elevated cholesterol levels that contribute to atherosclerosis and cardiovascular risk in HoFH patients.
Utilized when standard lipid-lowering agents are insufficient due to receptor defects in familial hypercholesterolemia.
Extended use to reduce the risk of cardiovascular events associated with high LDL-C in HoFH.
Complementary therapy with statins, PCSK9 inhibitors, and other lipid-modifying agents for enhanced efficacy.
Use in patients who require aggressive management of cholesterol levels despite specialized diet control.
Monitoring and management of patients at risk of liver toxicity due to novel mechanism of action.
Exploration in clinical trials for other severe hyperlipidemic conditions refractory to conventional treatments.
Approved by FDA specifically for HoFH, highlighting its niche application in rare lipid disorders.
As part of a comprehensive therapeutic regimen including lifestyle modifications and lipid monitoring.
Indicated only for patients confirmed to have HoFH; not for general hypercholesterolemia treatment.
Potential use in combination with vitamin E and essential fatty acid supplementation to mitigate side effects.
Managed under Risk Evaluation and Mitigation Strategy (REMS) due to safety profile.

Side Or Adverse Effects

Hepatotoxicity manifested by elevated liver transaminases and potential liver injury.
Gastrointestinal symptoms including nausea, vomiting, and abdominal pain/cramps.
Diarrhea and indigestion which may be dose-limiting during titration.
Fatigue and flu-like symptoms possibly related to liver effects or systemic responses.
Risk of steatosis (fatty liver) due to interference with hepatic lipid metabolism.
Rare allergic reactions including rash, hives, and anaphylaxis; requiring immediate discontinuation.
Loss of appetite associated with upper gastrointestinal distress.
Dark urine and jaundice indicative of liver dysfunction requiring urgent evaluation.
Potential decrease in absorption of fat-soluble vitamins A, D, E, and K leading to deficiency symptoms.
Light-headedness or presyncope related to electrolyte disturbances or dehydration secondary to diarrhea.
Risk of serious adverse reactions increases with concurrent CYP3A4 inhibitors.
Elevated liver enzymes necessitating regular monitoring and possible dose adjustments.
Stomach upset leading to reduced compliance if not managed properly.
Muscle pain and weakness have been reported, though less frequently compared to statins.
Possible interactions causing enhanced side effects with antifungal, antibiotic, and antiviral agents.

Precautions

Contraindicated in patients with moderate or severe hepatic impairment or active liver disease.
Require baseline and periodic liver function tests to monitor for hepatotoxicity.
Use effective contraception; Juxtapid is contraindicated during pregnancy due to teratogenicity.
Avoid high-fat meals during dosing to reduce gastrointestinal side effects and enhance drug tolerability.
Caution in patients with underlying gastrointestinal disorders as symptoms may be exacerbated.
Avoid concomitant use with strong CYP3A4 inhibitors to prevent elevated plasma levels of lomitapide.
Supplement with vitamin E and essential fatty acids as prescribed to prevent deficiencies.
Close monitoring in patients with alcohol consumption given increased risk of liver injury.
Dose escalation must be gradual with careful observation of tolerability and biochemical markers.
Inform patients about the importance of adherence to dosing instructions including fasting requirement.
Be vigilant for symptoms of liver dysfunction including nausea, abdominal pain, jaundice, and dark urine.
Adjust treatment regimen based on hepatic safety parameters and clinical response.
Educate patients on recognizing signs of serious adverse events requiring immediate medical attention.
Assess concomitant medications for potential drug-drug interactions before initiation.
Juxtapid should be managed under a Risk Evaluation and Mitigation Strategy (REMS) program.

Warnings

Do not use Juxtapid in patients with severe liver disease or active liver dysfunction.
Pregnancy contraindication due to risk of fetal harm; mandatory effective contraception required.
Potential for severe hepatotoxicity requiring regular liver function monitoring and discontinuation if necessary.
Grapefruit and grapefruit products must be avoided as they can increase lomitapide plasma concentration and toxicity.
Alcohol intake should be limited to no more than one drink per day to reduce liver injury risk.
Drug interactions with strong CYP3A4 inhibitors can cause life-threatening side effects.
Juxtapid is only available through a special restricted distribution program (REMS) to ensure safe use.
Risk of life-threatening allergic reactions; seek immediate care if symptoms occur.
Discontinue therapy if signs of severe diarrhea or gastrointestinal intolerance develop.
Patients may experience decreases in absorption of fat-soluble vitamins necessitating supplementation.
Lomitapide may reduce the efficacy of hormonal contraceptives if vomiting or diarrhea occur.
Do not crush, chew, or break capsules as this can alter drug release and increase adverse effects.
Dose must be individualized to reduce risk of toxicity while optimizing efficacy.
Avoid use in patients with a history of abnormal liver function tests without careful evaluation.
Close monitoring is warranted during up-titration phases due to increased adverse event incidence.

Contraindication

Pregnancy or suspected pregnancy due to teratogenicity risks.
Moderate or severe hepatic impairment or active liver disease at baseline or during therapy.
Known hypersensitivity or allergy to lomitapide or any product components.
Concurrent use with strong CYP3A4 inhibitors that markedly increase lomitapide plasma levels.
Patients unable to comply with necessary dietary fat restrictions and monitoring requirements.
History of abnormal liver function tests that do not normalize before starting therapy.
Severe gastrointestinal disease that may exacerbate lomitapide-induced GI symptoms.
Use in populations where safety and effectiveness have not been established (e.g., pediatric).
Concurrent use with drugs contraindicated with lomitapide as listed in prescribing information.
Patients with hereditary galactose intolerance or severe lactose deficiency due to capsule excipients.
Patients with significant alcohol abuse due to increased risk of hepatic injury.
Patients currently breastfeeding unless physician approval is given after risk-benefit analysis.
Inability or unwillingness to enroll or comply with REMS program requirements.

Drug Interactions

Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, and erythromycin increase lomitapide concentration leading to increased toxicity.
Concomitant use with certain HIV protease inhibitors (atazanavir, darunavir with ritonavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir) increases risk of adverse effects.
Co-administration with hepatitis C medications like boceprevir and telaprevir may result in significant drug interactions.
Antifungal agents including fluconazole, posaconazole, voriconazole pose interaction risks through CYP3A4 inhibition.
Certain antibiotics including ciprofloxacin, clarithromycin, erythromycin, telithromycin, and tetracycline derivatives may augment lomitapide plasma levels.
Heart or blood pressure medicines such as diltiazem and verapamil interact to increase lomitapide exposure.
Warfarin and other blood thinners may have altered effects when taken with lomitapide requiring close INR monitoring.
Cholesterol medications including atorvastatin and simvastatin may have additive or synergistic adverse reactions and require dose adjustments or monitoring.
Colesevelam and cholestyramine should be administered 4 hours apart from lomitapide to avoid reduced absorption.
Antidepressants and other psychoactive medications may have interactions through metabolism pathways.
Vitamin and supplement interactions may occur; take only prescribed doses as advised by the physician.
Concurrent use with isotretinoin, methotrexate, or tamoxifen requires evaluation due to potential hepatic effects.
Birth control pills may have reduced efficacy during lomitapide therapy with vomiting or diarrhea.
Many over-the-counter supplements and herbal products may interact; full disclosure to healthcare provider is essential.
Numerous drug-drug interactions necessitate thorough medication reconciliation and ongoing patient education.

Preparations Of The Drug

Juxtapid capsules are available in 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg strengths for oral administration.
Capsule shells contain gelatin and titanium dioxide as the main excipients; colorants include red and yellow iron oxides varying by dose.
Inactive ingredients include pregelatinized starch, sodium starch glycolate, microcrystalline cellulose, lactose monohydrate, silicon dioxide, and magnesium stearate to ensure capsule integrity and stability.
The imprinting ink comprises shellac, black iron oxide, and propylene glycol for capsule identification.
Formulated for stable shelf-life when stored at room temperature away from moisture and heat; do not freeze.
Manufactured by Amryt Pharmaceuticals DAC, Dublin, Ireland under strict pharmaceutical quality controls.
Supplied exclusively through certified pharmacies within the REMS program to ensure controlled distribution and patient safety.
Packaged in child-resistant bottles with precise labeling to ensure adherence to dosing and safety instructions.
Prescription-only legal status with detailed medication guides and patient counseling information provided with dispensing.
Not formulated as oral liquids, powders, or injectable preparations, requiring oral capsule administration adherence.